Mucoadhesive and muco-penetrating delivery systems for eradication of *Helicobacter pylori*

Saahil Arora, Gaurav Bisen, RD Budhiraja

Department of Pharmaceutics, Nanomedicine Research Centre, I.S.F. College of Pharmacy, Moga, Punjab, India

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*), a gram-negative microaerophilic spiral bacterium, has been found to be a major causative organism for peptic ulcer by Warren and Marshall in 1982. Around half of the world’s population is infected by this pathogen but only a small percentage of infected population shows clinical symptoms, which mainly depends upon the difference in bacterial virulence and hostile factor. *H. pylori* infection is present in 90–100% of duodenal ulcer patients and in 60–90% of gastric ulcer patients. Several studies have shown that *H. pylori* infection is associated with at least three- to four-fold increased risk of peptic ulcer diseases and that 10–15% of *H. pylori*-infected individuals will have peptic ulcer disease in their lifetime. *H. pylori* is the major causative organism of the chronic gastritis, peptic ulcer, B-cell MALT lymphomas, gastric carcinoma, and childhood malnutrition-associated carcinoma. All of these are associated with an increase in epithelial cell apoptosis.

WHO has listed *H. pylori*-associated gastric carcinoma as one of the three major causes of cancer-related deaths worldwide, around 0.5 million deaths every year. Chemotherapy of gastric cancer has poor clinical efficacy; however, the eradication of *H. pylori* infection could possibly prevent gastric carcinoma and other associated diseases. It is now well established that the maximum incidence of *H. pylori* infection is more in children of 11–16 years particularly for lower socioeconomic condition due to poor level of sanitation. The prevalence of *H. pylori* infection in India has been reported to be very high, ranging from 70% to 90% in patients with duodenal and peptic ulcer and 50% to 80% in patients with non-ulcer dyspepsia (NUD) as well as healthy asymptomatic adults. A triple therapy containing two antibiotics and one proton inhibitor over a period of 2 weeks is recommended worldwide for eradication of *H. pylori*. But poor stability of antibiotics in acidic environment and poor permeation of antibiotics across the mucus layer results in incomplete eradication of *H. pylori*. Various investigators have formulated novel gastro-retentive drug delivery systems such as floating systems, mucoadhesive systems, pH-sensitive gel systems, and muco-penetrating delivery systems for increasing the concentration of antibiotic in close proximity to the site of *H. pylori* infection. This review summarizes the novel drug delivery approaches investigated during the last few years and suggests that a high eradication rate can be achieved by therapy comprising of muco-penetrating delivery systems of antibiotics against *H. pylori*.

**Key words:** Colonization, eradication therapy, floating drug delivery, *Helicobacter pylori*, liposomes, muco-penetrating nanoparticles, mucoadhesive systems, pH-sensitive gel systems

---

**Access this article online**

Quick Response Code:  
Website: www.asiapharmaceutics.info  
DOI: 10.4103/0973-8398.100127
delivery systems like floating formulations, mucoadhesive drug delivery system, pH-sensitive gel system had been carried out for increasing the gastric residence and local concentration of drug at *H. pylori*-infected site. These studies indicated the benefit of targeting drug to the gastric mucosal layer by reducing the dose of antibiotic therapy as well as increased patient’s compliance. In this review, we summarize the current information on colonization of *H. pylori* and novel delivery system studies conducted in past few years, so as to utilize the information for future research on *H. pylori* eradication therapy [Figure 1].

### Colonization of *H. pylori*

*H. pylori* is a motile pathogen which lives deep in the gastric mucus layer close to the epithelial cells. In general, after the entry of any bacteria into the stomach, gastric acidity and peristaltic movement inhibit the adhesion and colonization of the bacteria in the gastric mucus layer. The continuously secreted mucus from glands of the epithelial cell pushes bacteria toward the luminal surface, where the more acidic environment retards the colonization and motility property of the pathogens. [13-15] However, even in these hostile conditions, *H. pylori* adheres to the mucus layer and penetrates deep in the mucus membrane close to the epithelial cells due to good motility of flagellae and various adhesins present on its surface as shown in Figure 2.

Once the bacterium establishes the adhesion with the mucus layer, the enzyme urease secreted by *H. pylori* metabolizes gastric urea to produce carbon dioxide and ammonia, which produces a surrounding coat of buffered acid. Earlier it was assumed that *H. pylori* usually colonizes in the mucus just close proximate to epithelial cell and do not penetrate the epithelial cells[16] but one of the recent study showed the invasion of *H. pylori* in the intercellular space of gastric epithelial cell.[17]

Thus, colonization of *H. pylori* in the gastric mucus layer is determined by various virulent and hostile factors as listed in Table 1. Urease and flagella are two most important virulent factors for successful colonization of *H. pylori*. [15,18,19] Among hostile factors, Lewis blood group antigens are most important factors for mucosal adhesions of bacteria. Based on composition, Lewis antigen are of two types: type 1, mainly distributed in the epithelium surface contain Le\(^a\), Le\(^b\), and sialyl-Le\(^a\), while type 2 located deeper in the mucus/parietal cell contain Le\(^b\), Le\(^i\), and sialyl-Le\(^a\). It is also well established that Le\(^a\) and Le\(^b\) are major hostile factors that are responsible for *H. pylori* adhesion to the gastric epithelial cell.[20] In addition to Lewis antigen, integrins are other factors for adhesion of *H. pylori*. Apart from lewis antigens, blood group antigen-binding adhesion (Bab A) protein[21] and Sialic acid-binding adhesion (Sab A) protein[22,23] are adhesion factors present on the outer membrane of *H. pylori*. Bab A and Sab A recognize hostile factors Le\(^b\) and Le\(^i\) respectively for adhesion on gastric epithelial cell.[22,23] Sheu et al. (2003) reported the expression of Le\(^b\) antigen as a cause behind nearly 73% of *H. pylori* infection. Once *H. pylori* adheres to the epithelial cell, it produces a direct injurious effect, which is amplified by production and release of vacuolating cytotoxin (VacA). [23,26]

### Current Treatment Regimen for Eradication of *H. pylori*

Treatment

Although, *H. pylori* is sensitive to many antibiotics during *in vitro* studies, yet no single antibiotic showed complete eradication *in vivo*. The various antibacterial agents used against *H. pylori* are reported in Table 2. Presently, these infections are treated with first-line triple therapy consisting of two antibiotics (amoxicillin along with clarithromycin/metronidazole) and a proton pump inhibitor (omeprazole/rabeprazole). The proton pump inhibitor increases the pH within stomach to facilitate the local action of antibiotics by increasing their stability, absorption, and tissue penetration.[34,35] A quadruple treatment regimen was also tried for eradication of *H. pylori*, which include colloidal bismuth subcitrate (CBS), tetracycline, metronidazole, and omeprazole.[36] This therapy had advantage over the triple therapy because bismuth precipitates in and around *H. pylori* pathogens leading to lysis of the bacterial cell wall within 2 h after ingestion of drug.[37] Also heavy metals such as zinc, nickel, and bismuth compounds interfere with the activity of urease enzyme. By combining complicated therapies in a single dosage form, a capsule (Helicide) of bismuth subcitrate, metronidazole, and tetracycline, an effort has been made to improve patient compliance.[38]

### Reason for Failure of *H. pylori* Treatment

In spite of various antibiotic combinations studied against *H. pylori*, none has shown complete eradication of the bacterium. The characteristic of *H. pylori* is its colonization

---

**Figure 1:** Pathophysiological conditions associated with *H. pylori*

**Figure 2:** Steps involved in colonization of *H. pylori*
and survival in deep gastric mucosa and also in the intercellular space between epithelial cells.\textsuperscript{[11,12]} Because of poor penetration power of antibiotics across the gastric mucus membrane, incomplete eradication results.\textsuperscript{[11,12]} The stability of commonly used antibiotics of triple therapy is another reason for treatment failure, which is not more than 3–4 h in gastric environment.\textsuperscript{[13]} The most important issue in management of\textit{H. pylori} is increased instances of antibiotic’s resistance. \textit{H. pylori} is known for its panmictic population structure\textsuperscript{[19,20]} i.e. genetic recombination is so frequent that it randomizes the DNA sequences and generates linkage equilibrium.\textsuperscript{[20]} There is general agreement that increasing antimicrobial resistance is related to the selection pressure exerted by the use of antibiotics. A significant variation in the resistance to antibiotics in \textit{H. pylori}, especially to metronidazole, amoxicillin, and clarithromycin, has been reported across the globe. Development of resistance against antibiotic is mainly responsible for the declining rate of \textit{H. pylori} eradication seen in many countries, more prominently in developing countries like China, India, Mexico, etc. A study in 2004 showed a 70% decline in eradication rates with clarithromycin-containing regimen in clarithromycin-resistant cases.\textsuperscript{[31]}

### Novel Drug Delivery Approaches for \textit{H. pylori}

Literature review reveals that local application of antibiotics to gastric mucosa resulted in better eradication compared to systemically available antibiotic.\textsuperscript{[42]} Hence, for effective eradication of \textit{H. pylori} the drug delivery system should adequately deliver the therapeutic agent in the close proximity of the gastric mucus membrane. In recent years, various novel approaches are used for increasing the gastric residence time of the delivery system and local action of the drug in stomach as shown in Figure 3. Different strategies utilized are: (i) density-based approaches including a high-density system and a low density system, (ii) the floating drug delivery system, (iii) the mucoadhesive/bioadhesive system and, (iv) the swelling system for improving the gastric retention time of the system.

### Table 1: Various virulent factors, their predictable role and association with \textit{H. pylori}

<table>
<thead>
<tr>
<th>Adhesions</th>
<th>Predicted role</th>
<th>Association with \textit{H. pylori}</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urease and its subunits urea, ureB</td>
<td>Survival in acidic environment, nutrient acquisition</td>
<td>Cytoplasmic, in part extracellular</td>
<td>Ghaira, 1997\textsuperscript{[27]}</td>
</tr>
<tr>
<td>Flagella and flagellins FlmA, FlxB</td>
<td>Motility</td>
<td>Extracellular, but enveloped by flagellar sheath</td>
<td>Ghaira, 1997\textsuperscript{[27]}</td>
</tr>
<tr>
<td>HspA, HspB</td>
<td>Heat shock proteins, Chaperonins</td>
<td>Intracellular, in part extracellular</td>
<td>Ghaira, 1997\textsuperscript{[27]}</td>
</tr>
<tr>
<td>Catalase</td>
<td>Detoxification of oxygen radicals ($H_2O_2$)</td>
<td>Intracellular, in part extracellular</td>
<td>Ghaira, 1997\textsuperscript{[27]}</td>
</tr>
<tr>
<td>CagA</td>
<td>Unknown function, marker for cag pathogenicity island</td>
<td>Cytoplasmic</td>
<td>Rad \textit{et al.}, 2002\textsuperscript{[23]}</td>
</tr>
<tr>
<td>VacA</td>
<td>Cytotoxic \textit{in vitro}</td>
<td>Secreted extracellular</td>
<td>Rad \textit{et al.}, 2002\textsuperscript{[23]}</td>
</tr>
<tr>
<td>BabA</td>
<td>Binds to fucosylated blood group antigens on cells</td>
<td>It has been implicated in peptic ulcer disease and gastric cancer</td>
<td>Rad \textit{et al.}, 2002\textsuperscript{[23]}</td>
</tr>
<tr>
<td>SabA</td>
<td>Binds to sialyl-Le$^a$ and sialyl-Le$^b$ antigens and involved in activation of neutrophils</td>
<td>None</td>
<td>Tannes \textit{et al.}, 2005\textsuperscript{[30]}</td>
</tr>
<tr>
<td>SabB</td>
<td>Binding specificity is unknown</td>
<td>Absence of SabB expression via phase variation is associated with duodenal ulcers</td>
<td>Tannes \textit{et al.}, 2005\textsuperscript{[30]}</td>
</tr>
<tr>
<td>AlpA and AlpB</td>
<td>Inactivation of the AlpA and AlpB genes result in decreased adherence to gastric epithelial cells</td>
<td>Outer membrane protein</td>
<td>Jonge \textit{et al.}, 2004\textsuperscript{[30]}</td>
</tr>
<tr>
<td>IceA</td>
<td>It encodes a CATG-recognizing restriction endonuclease</td>
<td>It has been associated to PUD, but its association is not universal</td>
<td>Figueiredo \textit{et al.}, 2000\textsuperscript{[31]}</td>
</tr>
<tr>
<td>DupA</td>
<td>The DupA gene encodes a VirB4 ATPase homolog</td>
<td>Associated with duodenal ulcers but also with reduced risk for gastric atrophy and cancer</td>
<td>Lu \textit{et al.}, 2005\textsuperscript{[32]}</td>
</tr>
<tr>
<td>OipA</td>
<td>OipA assist in IL-8 induction, but this association is not universal</td>
<td>Expression of OipA is linked to cag status and development of duodenal ulcers and gastric cancer</td>
<td>Kudo \textit{et al.}, 2004\textsuperscript{[33]}</td>
</tr>
</tbody>
</table>

\textsuperscript{CagA, the protein encoded by cytotoxin-associated gene A; FlmA and B, Flagellins A and B; HspA and B, heat shock proteins A and B; VacA, vacuolating cytotoxin A; BabA, blood group antigen-binding adhesin; SabA and B, Sialic acid-binding adhesin; AlpA and B, adhesions lipo proteins; IceA, induced by contact with epithelium; OipA, Outer membrane protein; DupA, duodenal ulcer promoting protein.}

}\textsuperscript{[38]}
Density-based approaches involve the density difference of formulation in comparison to normal stomach content density (~1.0004 g/cm$^3$). These systems improve sustained release of drug along with prolonging the gastric residence time of the dosage form. In high-density based systems, tablets with 1.5–2.4 g/cm$^3$ densities are prepared, but effectiveness of these systems in humans have not been observed. In the case of low density-based systems, bulk density is less than gastric fluid’s density and remains buoyant in stomach without affecting the gastric emptying rate for a prolonged period and releases the drug slowly. By entrapment of air (e.g. hollow chambers) or by incorporation of low-density materials (e.g. fatty materials, oils, or foam powder) low-density systems are prepared. Floating drug delivery systems are based on the use of the low-density polymer or gas-generating agents. In the case of gas-generating agent, gas generated is entrapped in the polymer matrix, thus provide the floating property to the drug delivery system. Bio/mucoadhesive systems comprise of natural or synthetic polymer(s) capable of adhering to a biological membrane (bioadhesive polymer) or the mucus lining of the GIT (mucoadhesive polymer) by forming non-covalent bonds with the mucin–epithelial surfaces. The adherence of the delivery system to the gastric wall increases residence time at a particular site, thereby improving bioavailability. Swelling/expanding systems swell to a size that prevents their passage through the pylorus. As a result, dosage form is retained in stomach for a long period of time. Sustained and controlled drug release may be achieved by selecting a polymer with high swelling properties due to physiochemical crosslink’s in the hydrophilic polymeric network. These systems may also erode in the presence of gastric juices.

Various researches based on these novel gastro-retentive systems against $H. pylori$ are summarized below:

**Floating systems**

Floating or hydrodynamically balanced systems (HBS) are simple, most approachable systems to provide high gastric residence time, and sustained release of drug. Floating tablets or buoyant systems using swellable polymers such as chitosan (CS), hydroxyl propyl methyl cellulose (HPMC), polyoxyethylene, carbops, polycarbophils, guar gum, etc., do not have sufficient trial documentation to be included in the efficacy comparison with the listed standard therapies. PPI: Proton-pump inhibitor; NSAID: Non-steroidal anti-inflammatory drug.
xanthan gum, etc. have been prepared for various drugs with or without CO₂-generating agent.[51-54]

A gastro-retentive dosage form of clarithromycin was formulated on the principle of buoyancy using different gel forming polymers.[51] Xanthan gum showed least possible lag time (35 s) but the integrity of tablet was poor. While in the case of Carbopol 934P, the lag time was much higher (16.5 minutes) and hydroxy propyl cellulose showed undesired floating characteristics. By optimizing the sodium bicarbonate content, floating tablets with desired floating lag time of about 3 min were obtained using hydroxy propyl methyl cellulose (HPMC). The report indicated that the floating and drug release profile of the tablet depends on the ratio of gas forming agent and polymer. The in vivo studies in humans for evaluation of the gastric residence time of tablet were found to be 220±30 min.

Another study on floating tablets of levofloxacin utilized HPMC and gelucire in the presence of sodium bicarbonate which increased the floating lag time range from 258 to 464 s.[52] The presence of gelucire, a release retarding hydrophobic polymer, resulted in the sustained effect. Another study prepared floating matrix tablets of clarithromycin using HPMC K4M, HPMC K100LV and sodium carboxy methyl cellulose (CMC sodium) as a release-controlling polymer and sodium bicarbonate as the gas-forming agent for buoyancy, showed prolonged gastric residence time in stomach and controlled release behavior with increased bioavailability.

More than 6 h in vivo buoyancy was observed in the case of famotidine-floating tablets using chitosan as a polymer and sodium bicarbonate and citric acid as the effervescent-generating system.[53]

These single unit buoyant formulations are associated with drawback of “all or none” system and require sufficiently high stomach fluid to be buoyant. Hence, depending on size, floating tablets may cross over to small intestine during house-keeper waves.[55,56] This serious limitation can be overcome by making the buoyant system which also adheres to the mucous lining of the stomach wall.[57] Among various mucoadhesive polymers, CS offers a great advantage being polycationic in nature and also has some antibacterial activities. However, adhesion failure may occur when overhydration converts the chitosan gel network to slippery mucilage in gastric environment.[58] Therefore, the addition of other types of biodegradable polymers in the delivery system may provide control over the swelling of CS and thereby preventing adhesion failure.

**Mucoadhesive systems**

Mucoadhesive drug delivery systems are most suitable for local drug delivery in the gastric mucus layer. These systems provide an intimate contact with the mucus membrane for drug diffusion without acidic degradation. There are many theories given for the mechanisms of mucoadhesion like polyvalent adhesive interaction,[59] electrostatic attraction, H-bond formation, vander-Waal force, and other.[60] The gastric mucus mainly contains a negative charge on their surface due to the presence of carboxyl, sulfate group, and sialic acid in the mucus glycoprotein and hence mucoadhesion occurs by electrostatic attraction force. For the effective mucoadhesion, the drug delivery system should be positively charged. Figure 4 shows the different strategies for eradication of *H. pylori* by using microparticles/microspheres and nanoparticles.

**Microspheres/beads**

Microspheres or microcapsules are multi-particulate systems, preferred over the conventional dosage forms like tablet and capsule because of their increased surface area, thus increasing the absorption of the drug, reducing the dosing frequency, and improving the patient compliance. Such systems with a mucoadhesive property release the entrapped drug in proximity to the mucosal layer and beneficial for local treatment and enhanced bioavailability.

In 2000, Wang et al.[61] prepared positively charged modified gelatin microspheres of amoxicillin for the eradication of *H. pylori*. The aminated gelatin microspheres showed much higher mucoadhesion with gastric mucosa than gelatin microspheres for improving the mucoadhesion property. This is attributed to the strong electrostatic interaction between higher amino group content in modified gelatin and the mucus membrane. Increasing the concentration of the cross-linking agent like glutaraldehyde decreases the free amino group content of gelatin, which decreases the mucoadhesion property of microspheres. This study showed that the amino group content or the cationic charge on a polymer plays a crucial role in the mucoadhesion property of the particulate system.

Stability of antibiotic in acidic environment is one of the major limitations for the local delivery of drug in stomach.
Several studies have been conducted for assessment of stability of antibiotics like amoxicillin, clarithromycin, metronidazole, most commonly used in *H. pylori* treatment. It is well documented that these antibiotics are unstable at acidic pH below 2. In 2005, Liu et al. prepared a amoxicillin-loaded mucoadhesive microsphere of ethyl cellulose and carbomer 937 by the solvent evaporation method and observed low acidic degradation of amoxicillin in the prepared microspheres. Also, mucoadhesive microspheres of amoxicillin could stay in the gastrointestinal tract for a longer period of time and resulted in higher *H. pylori* clearance.

Patel and Patel (2007) formulated chitosan mucoadhesive microspheres of amoxicillin by the emulsification phase separation technique using glutaraldehyde as a cross-linking agent. Microspheres were discrete, spherical, free flowing, showing high drug entrapment efficiency and strong adherence to the gastric mucous layer. The prepared amoxicillin mucoadhesive microspheres showed increased gastric retention, gastric stability of amoxicillin, and better clearance effect than amoxicillin powder.

In 2009, Patel and Chavda developed mucoadhesive amoxicillin microspheres using carbopol-934P as a mucohesive polymer and ethyl cellulose as a carrier polymer by the emulsion–solvent evaporation technique. The optimized formulation exhibited 80% mucoadhesion after 1 h and *in vivo* *H. pylori* clearance tests on amoxicillin mucoadhesive microspheres under fed conditions at single dose or multiple oral dose(s) showed better clearance effect than amoxicillin powder.

Narkar et al., 2010, developed amoxicillin-loaded mucoadhesive gellan beads by the cation-induced ionotropic gelation method using acidic and alkaline cross-linking media. The beads prepared in an alkaline cross-linking medium showed higher yield and entrapment efficiency than the acidic cross-linking medium. Chitosan-coated gellan beads exhibited *in-vitro* drug release up to 7 h in a controlled manner. Complete growth inhibition of *H. pylori* was observed due to good mucoadhesion of beads.

The mucoadhesive formulations face a drawback of washing out from stomach along with the mucus layer. As the mucus layer turn out from stomach, it carries the adhesive particles along with to intestine. This is a major limitation of the mucoadhesive system in the treatment of *H. pylori* eradication.

To sort out this problem, some researcher tried to formulate floating bioadhesive microspheres for prolonging the gastric retention time. In 2002, Umamaheswari et al. utilized both the above mechanisms for improving the gastric residence time of the drug delivery system by preparing cellulose acetate butyrate (CAB)-coated cholestyamine microcapsule of acetohydroxamic acid (AHA) along with a gas-generating agent, sodium bicarbonate. The buoyancy of prepared microcapsules was about 85% till 12 h, sufficient time for effective delivery of drug to stomach. Higher coat to core ratio and sodium bicarbonate content resulted in high buoyancy. Because of CAB coating on the cholestyamine, electrostatic charge got hindered which decreased the mucoadhesion of microcapsules compared to the uncoated resin–drug complex. In 2003, the same group of researcher prepared AHA-loaded polycarbonate (PC) hollow microspheres by the emulsion solvent evaporation method in the size range of 240–288 mm for improving the gastric retention property of dosage form.

Ishak et al. 2006 prepared chitosan-treated alginate beads of metronidazole by the ionotropic gelation method. Histopathological examination of mice stomach after the *in vivo* *H. pylori* clearance test using 5, 10, 15, and 20 mg/kg as single daily dose for 3 successive days showed 100% clearance rate with 15 mg/kg dose of metronidazole-loaded chitosan-treated alginate beads in comparison to only 33.33% with 20 mg/kg dose of metronidazole suspension.

In 2007, Rajnikanth and Mishra prepared floating bioadhesive beads of AHA using gellan gum as a polymer. AHA can permeate intact bacterial cells and play an important role in the chemotactic motility of *H. pylori*. Gellan gum has the property of temperature dependent and cation-induced gelation property. The prepared floating beads of gellan by cross linking with calcium ions showed the barrier property in acidic medium and also resulted in the sustained release matrix system.

**Mucoadhesive in situ Gels**

The liquid gel system has an advantage of patient compliance due to ease of administration. Also, the mucoadhesive polymeric gel system forms a protective layer over the gastric mucosal surface, thus preventing mucosa from further acidic damage.

In 2007, Rajnikanth et al. prepared floating *in situ* gel system of gellan gum and calcium carbonate for local delivery of amoxicillin in stomach. The formulation showed sol to gel rheological property due to gelation of gellan in acidic environment and cross linking with calcium ion. In an acidic condition, carbon dioxide generated from calcium carbonate got entrapped in the gel matrix to show buoyancy. Higher concentration of calcium carbonate resulted in rapid and rigid gel in minimum time, which helped the formulation to stay in stomach for more than 24 h against peristaltic movement. The *in vivo* *H. pylori* clearance study showed higher efficacy of amoxicillin *in situ* gel in dose of 1.0 mg/kg compared to 10 mg/kg amoxicillin suspension.

**Mucoadhesive Nanoparticles**

Floating or mucoadhesive microparticulate systems release...
their content in gastric medium or on the surface of gastric mucosa. Thus, the mucus penetration property of drug is essential for effective clearance of *H. pylori*. So it is believed that particle with nanometric size with mucoadhesive property can adhere to gastric mucosa and infiltrate deep into the mucus membrane toward the gastric epithelial cell and even protect the drug from degradation by acidic environment.

Nanoparticles are made from biocompatible and biodegradable materials such as polymers, either natural (gelatin, albumin), synthetic (polylactides, polyalkyl cyanoacrylates), or solid lipids. In body, drug loaded in nanoparticles is released from matrix by diffusion, swelling, erosion, or degradation. Advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, drug targeting and feasibility of variable routes of administration including oral and inhalation.

In 2008, Ramteke and Jain prepared and evaluated oral mucoadhesive-sustained release nanoparticles of clarithromycin and omeprazole against *H. pylori* in order to improve patient compliance and therapeutic effect by reducing dose-related side effects.\(^{[76]}\) This study observed the long residence period of drug-containing nanoparticles in the stomach, which is not possible with conventional systems. They concluded that drug-containing gliadin nanoparticles with dual therapy may provide greater antibacterial activity than the plain drug formulations.

In 2010, Chang et al. prepared amoxicillin-loaded chitosan-poly-g-glutamic acid nanoparticles by the ionic gelation method and incorporated in the pH-sensitive calcium alginate–gelatin gel for preventing the acidic degradation of nanoparticles.\(^{[77]}\) The effect of pH on the stability of chitosan-poly-g-glutamic acid nanoparticles indicated the instability and protonation of the carboxylic group of g-glutamic acid at pH 1.2 and pH 7.0, resulting in collapse of nanoparticles. Degradation of nanoparticles at pH 1.2 results in burst release of drug and hence for controlled drug release and stability of nanoparticles, incorporation of nanoparticles in pH-sensitive gel was proposed. According to researcher’s proposal, hydrogels first adhere to the gastric mucosa in acidic environment and then swell or disintegrate, followed by release of incorporated nanoparticles at suitable pH condition of the gastric mucosal surface. This resulted in deep infiltration of drug-loaded nanoparticles into the mucus membrane. In the presence of type A gelatin, a positively charged polymer, sodium alginate, interacts with Ca\(^{2+}\) ions to form polyionic hydrogel. The swelling characteristics of the gel studied at different pH conditions showed shrinking of hydrogel at acidic pH (≤4) due to hydrogen bond formation between the -COOH and -OH group, which helps in protection of entrapped nanoparticles from acidic degradation. At higher pH, the carboxylic acid group of alginate gets deprotonated, resulting in formation of carboxylate ions, which cause an expulsive force within the gel due to electrostatic repulsion to release of the incorporated nanoparticles.

Moogooee et al. (2011) prepared novel amoxicillin-loaded nanoparticles using cross-linked N-isopropyl acrylamide-acrylic acid-hydroxyethyl methacrylate, which due to its mucoadhesive property delivered the drug in close proximate of gastric mucosa.\(^{[77]}\)

### Liposomes

Liposomes are concentric bilayered vesicles mainly composed of natural and synthetic phospholipids enclosing an aqueous core. Lipid molecules are usually phospholipid–amphipathic moieties with a hydrophilic head group and two hydrophobic lipid tails. On addition of excess water, such lipidic moieties spontaneously originate to give the most thermodynamically stable conformation, in which polar head groups face outwards into aqueous medium, and the lipidic chains turns inward to avoid the water phase, giving rise to double layer or bilayer lamellar structures. Both water and lipid soluble drugs can be entrapped into the liposomes. Hydrophilic drugs can be entrapped in aqueous environment and lipophilic drugs remain within the bilayer region.

Umamaheshwari and Jain, 2004, formulated AHA-loaded phosphatidyl ethanolamine (PE) liposomes anchored polyvinyl alcohol (PVA) xerogel beads (lipobeads) as a receptor-mediated drug delivery system for use in blocking adhesion of *H. pylori*.\(^{[78]}\) PVA beads containing AHA were prepared by emulsification followed by the low-temperature crystallization method. Surface acylation with a fatty acid chain was accomplished by treating PVA bare beads with palmitoyl chloride. The inhibitory efficacy of lipobeads was significantly higher compared to that of PVA bare beads, proving their potential as the targeted drug delivery system in the treatment of *H. pylori*.

Bardonnet et al., 2009, prepared fucosylated-targeted liposomes loaded with antimicrobial agents (ampicillin and metronidazole) against *H. pylori*.\(^{[79]}\) Incorporation of fucosylated glycolipids in the vesicle membrane leads to liposome–bacteria interactions, in both spiral and coccoid forms of bacteria. The formulated liposomes seemed to be promising against *H. pylori* infection.

Jain et al., 2009, designed a gastro-retentive drug delivery system incorporated with amoxicillin and metronidazole, specifically suited for the eradication of *H. pylori*.\(^{[80]}\) The system possessed the advantages of both vesicular and particulate carriers, and it was prepared by alternative coating of polyanion (poly(acrylic acid), PAA) and polycation (poly(allylamine hydrochloride), PAH) using liposomes as the core. They compared the conventional liposomes and the polyelectrolyte based multi-layered system (nanocapsules)
and found that multi-layered system gave prolonged drug release in simulated gastric fluid, suitable for drug delivery against \textit{H. pylori} infection. Newly developed composite nanocapsules of combination therapy proved to have commendable potential in \textit{H. pylori} eradication as compared to conventional drug delivery systems.

**Targeted Nanoparticles**

The most prominent advantage of the nano-colloidal drug delivery system over the conventional delivery system is the option of selective delivery to the site of action and hence termed as targeted drug delivery. Active targeting can be achieved by modification of the polymeric colloidal particles’ surface by attaching some ligand or targeting entity, which have affinity toward bacteria.

Some researchers found lectin-binding affinity of carbohydrates present on microorganisms such as \textit{Helicobacter} \cite{81,82} and \textit{Streptococcus} \cite{83}. In 2000, Khet et al. found mannose- and fucose-specific carbohydrate residue on bacterial surface during the lectin–agglutination assay.\cite{84} Probably, these residues may help in adherence of bacteria to the gastric mucosal layer or epithelial cells. A carbohydrate moiety present on bacterial surface may contribute in targeting the drug delivery system for \textit{H. pylori}. Hence, it was proposed that the lectin-conjugated nanoparticulate system may bind to the carbohydrate residue present on the bacterial surface and hence shall play an effective tool for eradication of \textit{H. pylori}.

Umamaheswari and Jain (2003) prepared AHA-loaded glidian nanoparticles conjugated with lectins \textit{[UlexEuropaeus Agglutinin I (UEA I) and Conconavalin A (Con A)]} with average size of 412 nm, zeta potential 26 mV, and 72% drug entrapment efficiency.\cite{85} Lectin conjugation inhibited initial burst release of AHA due to covering of surface adsorbed drug. Also, lectin conjugation increased interaction of nanoparticles with mucus by four folds and interaction between \textit{H. pylori} and lectin-conjugated formulation as confirmed by the agglutination assay. In \textit{vitro} \textit{H. pylori} growth inhibition results showed almost two-fold increased inhibition for lectin-conjugated glidian nanoparticles than glidian nanoparticles.

In 2008, Ramteke \textit{et al.} also studied lectin-conjugated nanoparticles containing drug combinations of amoxicillin, clarithromycin, and omeprazole, a standard therapy for eradication of \textit{H. pylori}.\cite{86} The triple drug regimen showed a synergistic and additive effect on the eradication study. The same research group in 2009 reported triple drug therapy-based fucose-conjugated chitosan–glutamate nanoparticles for eradication of \textit{H. pylori}.\cite{87} The triple therapy included proton pump inhibitor, omeprazole, and antibiotics, amoxicillin and clarithromycin, that minimized the chances of drug resistance and provided better gastric stability.\cite{87,88} The ionic interaction of chitosan and glutamic acid decreased the rapid release of the drug from the nanoparticles due to low solubility of glutamate salt in acidic medium. Conjugation of fucose on chitosan–glutamate nanoparticles may assist targeting of nanoparticles on \textit{H. pylori} and also help in sustained release of drug from nanoparticles (\textasciitilde 80% in 8 h). Histopathological studies after the \textit{H. pylori} eradication study showed higher eradication than plain drug or simple nanoparticles. Thus, systems with increased potential of gastric retentivity due to the mucoadhesive property of polymer and with targeting affinity for \textit{H. pylori} in the presence of lectins and fucose on the nanoparticles surface could be one of the possible delivery systems for eradication of \textit{H. pylori} in near future.

**Muco-penetrating Systems**

Mucoadhesion though increases the gastric residence time of particles, thick viscoelastic mucosal gel does not allow antimicrobial drugs to penetrate through it uniformly. Swelling of polymer may hinder docking it in gastric mucus and strong mucoadhesion decreases mobility and thus inter-penetrability into mucus.\cite{89} In addition, gastric motility and proteolytic activity make mucus turnover intense, thereby making gastric residence of formulation shorter. Hence, efficient adherence to mucus could make the system incapable of penetrating across the mucus layer and entering the underlying epithelia.\cite{90}

To overcome limitations of mucoadhesive systems, particulate systems are required to penetrate the mucus membrane and deliver the drug in close proximity to the site of \textit{H. pylori} infection. Many researchers reported particulate systems capable of penetrating the mucus membrane. Some of these reports include polyethylene glycol (PEG)-coated polystyrene-based non-adhesive nanoparticles effectively penetrating sputum of cystic fibrosis patients,\cite{91} PEG-PSA(poly sebacic acid)-based biodegradable nanoparticles rapidly penetrating the human mucus barrier,\cite{92} insulin-loaded polyethylene glycol-grafted chitosan (PEG-g-chitosan) nanoparticle for the nasal absorption,\cite{93} DNA-coated biodegradable (poly lactide co-glycolic acid) PLGA nanoparticle for the gene delivery in gastric mucus.\cite{89} These studies emphasized on modifying the surface chemistry of the particulate system such as CS, to minimize the mucoadhesion property by shielding the cationic charge. Along with shielding charge, particle size may also play a very crucial role in penetration of particles. Particle size less than mesh size of mucus fiber are reported to exhibit good mucus penetration property.\cite{76}

In 2009, Lin \textit{et al.}\cite{90} prepared pH responsive chitosan–heparin nanoparticles for stomach-specific delivery of antibiotics in \textit{H. pylori} eradication. They used chitosan for its mucoadhesive and antimicrobial properties and heparin for its anticoagulant property in accelerating ulcer healing and mucosal regeneration. For gastric mucosal adhesion, infiltration of nanoparticles deep into the mucus layer and effective delivery of drug near epithelial cells, the particulate
system must have smaller size less than 200 nm and a low zeta potential value. Particle size of nanoparticles at pH 1.2–2.5 was larger compared to that at pH 4.5–6.5 which may be due to the protonation of amino groups [NH\(_2\)] of chitosan and the carboxylic ions [-COO\(^-\)] on heparin at low pH resulting in a polyelectrolyte complex with relatively weaker electrostatic interaction. The study revealed that nanoparticles are stable in acidic conditions and able to protect the antibiotic agent. Prepared nanoparticles infiltrate deep into mice stomach where breakdown of nanoparticles resulted in drug release due to lysosomal degradation and cytoplasm pH of epithelial cells. This pH-sensitive nanoparticulate system satisfied requisite conditions for drug delivery against H. pylori.

Another study by Arora et al., 2011,\(^{[97]}\) showed a novel muco-penetrating CS-ALG PEC nanoparticulate system composed of chitosan and sodium alginate. According to researchers, by electrostatic interactions between anionic groups from sodium alginate and cationic groups from chitosan, a microporous matrix structure of the polyelectrolyte complex can be formed which results in decreased mucoadhesion and increased muco-penetration as well as localization of nanoparticles in the deep mucosal region can be obtained. Results proved the concept of increased mobility of nanoparticles in the gastric mucus by decreasing the surface charge on polymers like chitosan and its utilization for transmucosal delivery of antibacterial drugs in eradication of H. pylori.

A summarized report on the novel delivery systems investigated against eradication of H. pylori is presented in Table 3.

### CONCLUSION

In gastric ulcers caused by H. pylori, the treatment requires high concentration of antibacterial agents like clarithromycin or metronidazole or amoxicillin in stomach and absorption through gastric mucosa. However, presently available conventional drug deliveries of these drugs fail to achieve the same. A lot of remarkable novel drug delivery approaches making use of buoyancy and bioadhesion to increase the gastro-retention time have been developed for the treatment of H. pylori infection. Among many novel delivery systems investigated so far for gastric delivery of drugs for H. pylori, the nanoparticulate system showed the great potential for the selectively delivering the drug at infection site. By modifying the surface groups present on mucoadhesive polymers, increased mobility of nanoparticles in the gastric mucus can be obtained for better eradication of H. pylori. These systems are associated with major problems like stability on prolonged storage, consistency of drug entrapment, drug release and industrial scale up.

### ACKNOWLEDGEMENTS

The authors are grateful to Prof. R. S. R. Murthy for kind guidance in the final outcome of this manuscript and Mr. Parveen Garg, Chairman, ISF College of Pharmacy, Moga, for providing facilities and financial assistance during the project.

<table>
<thead>
<tr>
<th>Polymers used</th>
<th>Drug</th>
<th>Mechanism</th>
<th>Salient features</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-Matrix tablets</td>
<td>Clarithromycin</td>
<td>Floating system in presence of NaHCO(_3)</td>
<td>In vitro FLT-33 s, Buoyancy&gt;12 h, In-vivo Gastric retention 220 min</td>
<td>Nama et al., 2008(^{[51]})</td>
</tr>
<tr>
<td>HPMC K4M, Carbopol, Xanthan Gum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelucire43/01, HPMC K4M, sod. carbonate</td>
<td>Levofloxacin</td>
<td>Floating tablet</td>
<td>In-vitro floating time – 10 hours, FLT decrease with increase in HPMC conc.</td>
<td>Thakker et al., 2008(^{[52]})</td>
</tr>
<tr>
<td>HPMC, Sod. CMC</td>
<td>Clarithromycin</td>
<td>Controlled release floating tablets</td>
<td>In-vitro floating time – 12.5 h, percent drug release at 12 h was 99.99%</td>
<td>Barhate et al., 2009(^{[53]})</td>
</tr>
<tr>
<td>Chitosan, MCC</td>
<td>Famotidine</td>
<td>Floating tablets</td>
<td>Buoyancy time more than 6 h</td>
<td>Gnanaprakash et al., 2010(^{[54]})</td>
</tr>
<tr>
<td>B-Mucoadhesive Microspheres/beads</td>
<td>Amoxicillin</td>
<td>Microspheres</td>
<td>Increase mucoadhesion</td>
<td>Wang et al., 2000(^{[55]})</td>
</tr>
<tr>
<td>Modified gelatin</td>
<td></td>
<td></td>
<td></td>
<td>Liu et al., 2005(^{[60]})</td>
</tr>
<tr>
<td>Ethyl cellulose and carborner 937</td>
<td>Amoxicillin</td>
<td>Microspheres</td>
<td>Protection of drug in stomach</td>
<td>Patel and Patel, 2007(^{[66]})</td>
</tr>
<tr>
<td>chitosan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbopol-934P</td>
<td>Amoxicillin</td>
<td>Microspheres</td>
<td>80% mucoadhesion after 1 h, Better H. pylori clearance effect than amoxicillin powder</td>
<td>Patel and Chavda 2009(^{[67]})</td>
</tr>
</tbody>
</table>

CONTd...
<table>
<thead>
<tr>
<th>Polymers used</th>
<th>Drug</th>
<th>Mechanism</th>
<th>Salient features</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAB and cholestyamine</td>
<td>AHA</td>
<td>Microspheres</td>
<td>Increase gastric retention time up to 12 h</td>
<td>Umamaheswari et al., 2002[89]</td>
</tr>
<tr>
<td>Polycarbonate</td>
<td>AHA</td>
<td>Microspheres</td>
<td>Increase gastric retention time up to 12 hours</td>
<td>Umamaheswari et al., 2003[70]</td>
</tr>
<tr>
<td>Chitosan and sodium alginate</td>
<td>Metronidazole</td>
<td>Beads</td>
<td>High in vivo H. pylori activity with 50% reduction in dose</td>
<td>Ishak et al., 2006[71]</td>
</tr>
<tr>
<td>Gellan gum</td>
<td>Clarithromycin</td>
<td>Beads</td>
<td>Better H. pylori clearance effect than clarithromycin suspension</td>
<td>Rajnikanth and Mishra, 2008[72]</td>
</tr>
<tr>
<td>C-Mucoadhesive Gels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gellan gum in the presence of</td>
<td>Amoxicillin</td>
<td>In-situ gel in</td>
<td>High in vivo H. pylori clearance with 1.0 mg/kg amoxicillin in situ gel compare to 10 mg/kg amoxicillin suspension</td>
<td>Rajnikanth et al., 2007[74]</td>
</tr>
<tr>
<td>calcium carbonate</td>
<td></td>
<td>acidic pH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-Mucoadhesive Nanoparticles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gliadin</td>
<td>Clarithromycin and omeprazole</td>
<td>Nanoparticles</td>
<td>The gliadin nanoparticles showed high drug entrapment, yield and greater eradication in vitro effect.</td>
<td>Ramteke and Jain, 2008[75]</td>
</tr>
<tr>
<td>Chitosan, Poly-γ-glutamic acid</td>
<td>Amoxicillin</td>
<td>Nanoparticles in pH-sensitive gel</td>
<td>Increased drug stability in stomach and sustained drug release</td>
<td>Chang et al., 2010[76]</td>
</tr>
<tr>
<td>Sod. alginate, Gelatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cross-linked N-isopropyl-acrylamide-acrylic acid- hydroxyethyl methacrylate</td>
<td>Amoxicillin</td>
<td>Nanoparticles</td>
<td>Increases drug penetration in gastric mucosa</td>
<td>Moogooee et al., 2011[77]</td>
</tr>
<tr>
<td>E-Liposomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphatidyl ethanolamine, polyvinyl alcohol</td>
<td>AHA</td>
<td>Multilayered liposomal delivery</td>
<td>Mucoadhesion, active targeting at the bacterial surface hence higher eradication rate</td>
<td>Umamaheshwari and Jain, 2004[78]</td>
</tr>
<tr>
<td>Fucose-linked glycolipids</td>
<td>Ampicillin, metronidazole</td>
<td>Multilayered liposomal delivery</td>
<td>The presence of cholesterol in liposomes helped in specific interaction with H. pylori surface and better eradication in presence of antibiotics.</td>
<td>Bardonnet et al., 2008[79]</td>
</tr>
<tr>
<td>Poly acrylic acid, poly allylamine liposomes</td>
<td>Amoxicillin, metronidazole</td>
<td>Multilayered liposomal delivery</td>
<td>The system showed prolonged drug release in SGF, successful in vitro activity and surface binding to H. pylori</td>
<td>Jain et al., 2009[80]</td>
</tr>
<tr>
<td>F-Targeted Nanoparticles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UEA I and Con A-conjugated gliadin nanoparticles</td>
<td>AHA</td>
<td>Nanoparticles</td>
<td>Mucoadhesion, active targeting at the bacterial surface hence higher eradication rate</td>
<td>Umamaheswari and Jain, 2003[85]</td>
</tr>
<tr>
<td>Lectin-conjugated gliadin</td>
<td>Amoxicillin, Clarithromycin and omeprazole</td>
<td>Nanoparticles</td>
<td>Triple therapy show better eradication profile due to synergetic and additive effect with active targeting</td>
<td>Ramteke et al., 2008[86]</td>
</tr>
<tr>
<td>nanoparticles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fucose-conjugated chitosan-glutamate</td>
<td>Amoxicillin, Clarithromycin and omeprazole</td>
<td>Nanoparticles</td>
<td>Controlled the release behavior of drug from nanoparticles with selective targeting</td>
<td>Ramteke et al., 2009[87]</td>
</tr>
<tr>
<td>G-Mucopenetrating Nanoparticles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chitosan</td>
<td>-</td>
<td>Nanoparticles</td>
<td>Muco-penetration into deep gastric mucosal layer</td>
<td>Arora et al., 2010[87]</td>
</tr>
<tr>
<td>Chitosan– Alginate</td>
<td>Amoxicillin</td>
<td>Nanoparticles</td>
<td>Muco-penetration into deep gastric mucosal layer</td>
<td>Arora et al., 2010[87]</td>
</tr>
</tbody>
</table>
REFERENCES

Helicobacter pylori: Behavior in acidic conditions.


How to cite this article: Arora S, Bisen G, Budhiraja RD. Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori. Asian J Pharm 2012;6:18-30.

Source of Support: I. S. F. College of Pharmacy, Moga. Conflict of Interest: None declared.